Abstract:Human cystic echinococcosis is a chronic, complex and neglected infection. Its clinical management has evolved over decades without adequate evaluation of efficacy. Recent expert opinion recommends that uncomplicated inactive cysts of the liver should be left untreated and solely monitored over time (“watch-and-wait” approach). However, clinical data supporting this approach are still scant and published mostly as conference proceedings. In this study, we report our experience with long-term sonographic and se… Show more
“…Specific antibodies may be detectable for years in the presence of stably inactive cysts and even after radical surgery and do not imply the presence of active infection. [16][17][18][19] As a result, clinicians with little experience with this disease infer that positive serology always means presence of active infection, a wrong assumption often resulting in unnecessary treatment, with attendant side effects, cost, and patient (and physician) anxiety. A good understanding of the behavior of serology and its influencing variables, beyond stage of cysts, is crucial for the diagnosis and clinical management of CE, and allows clinicians to evaluate serology results in the context of each patient's condition.…”
Abstract. Knowledge of variables influencing serology is crucial to evaluate serology results for the diagnosis and clinical management of cystic echinococcosis (CE). We analyzed retrospectively a cohort of patients with hepatic CE followed in our clinic in 2000-2012 to evaluate the influence of several variables on the results of commercial enzymelinked immunosorbent assay (ELISA) and indirect hemagglutination (IHA) tests. Sera from 171 patients with ≥ 1 hepatic CE cyst, and 90 patients with nonparasitic cysts were analyzed. CE cysts were staged according to the WHO-IWGE classification and grouped by activity. A significant difference in ELISA optical density (OD) values and percentage of positivity was found among CE activity groups and with controls (P < 0.001). The serological response was also influenced by age (P < 0.001) and cyst number (P = 0.003). OD values and cyst size were positively correlated in active cysts (P = 0.001). IHA test showed comparable results. When we analyzed the results of 151 patients followed over time, we found that serology results were significantly influenced by cyst activity, size, number, and treatment ≤ 12 months before serum collection. In conclusion, serological responses as assessed by commercial tests depend on CE cyst activity, size and number, and time from treatment. Clinical studies and clinicians in their practice should take this into account.
“…Specific antibodies may be detectable for years in the presence of stably inactive cysts and even after radical surgery and do not imply the presence of active infection. [16][17][18][19] As a result, clinicians with little experience with this disease infer that positive serology always means presence of active infection, a wrong assumption often resulting in unnecessary treatment, with attendant side effects, cost, and patient (and physician) anxiety. A good understanding of the behavior of serology and its influencing variables, beyond stage of cysts, is crucial for the diagnosis and clinical management of CE, and allows clinicians to evaluate serology results in the context of each patient's condition.…”
Abstract. Knowledge of variables influencing serology is crucial to evaluate serology results for the diagnosis and clinical management of cystic echinococcosis (CE). We analyzed retrospectively a cohort of patients with hepatic CE followed in our clinic in 2000-2012 to evaluate the influence of several variables on the results of commercial enzymelinked immunosorbent assay (ELISA) and indirect hemagglutination (IHA) tests. Sera from 171 patients with ≥ 1 hepatic CE cyst, and 90 patients with nonparasitic cysts were analyzed. CE cysts were staged according to the WHO-IWGE classification and grouped by activity. A significant difference in ELISA optical density (OD) values and percentage of positivity was found among CE activity groups and with controls (P < 0.001). The serological response was also influenced by age (P < 0.001) and cyst number (P = 0.003). OD values and cyst size were positively correlated in active cysts (P = 0.001). IHA test showed comparable results. When we analyzed the results of 151 patients followed over time, we found that serology results were significantly influenced by cyst activity, size, number, and treatment ≤ 12 months before serum collection. In conclusion, serological responses as assessed by commercial tests depend on CE cyst activity, size and number, and time from treatment. Clinical studies and clinicians in their practice should take this into account.
“…12,13 Uncomplicated inactive CE4 and CE5 cysts do not have to be treated but only followed over time with US. 2,14 Despite the availability of the WHO-IWGE classification as a guidance for treatment, allowing a rational, comparable, and safe approach to CE, an online survey conducted in 2014 on the treatment options that clinicians around the world would choose in five clinical cases of CE found not only extremely heterogeneous managements of the same cases but also a *Address correspondence to Marin Muhtarov, Gastroenterology Ward, Multi-Profile Hospital for Active Treatment "Kardzhali," 19 Trakya Boulevard, 6600 Kardzhali, Bulgaria. E-mail: mukhtarov@ abv.bg worrying number of practices that are either unsafe or not recommended.…”
Abstract. Cystic echinococcosis (CE) is a clinically complex chronic parasitic disease, management options for which include surgery, percutaneous treatments, and treatment with albendazole (ABZ) for active cysts, and the "Watch-andWait" approach for uncomplicated, inactive cysts. We examined, retrospectively, the clinical management of 334 patients with hepatic CE from the southeastern Rhodope region of Bulgaria between 2004 and 2013. Cysts were reclassified according to the World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) on the basis of ultrasound reports and images. The majority (62.3%) of uncomplicated cysts were CE1, 66% of which were treated surgically. Of all interventions, 5% were performed on inactive uncomplicated CE4-CE5 cysts. About half (47.6%) of these cysts were therefore treated inappropriately, exposing patients to unnecessary treatment-related risks and the health system to unnecessary costs. No management change was observed after the publication of the WHO-IWGE Expert Consensus recommendations in 2010. In Bulgaria, ABZ is still used in interrupted cycles as this is reimbursed, and peri-interventional chemoprophylaxis was not administered in the majority of surgical patients. Efforts are needed to introduce the WHO-IWGE classification and management recommendations and to encourage reception of state-of-the-art practices by public health regulatory bodies to improve patient quality of care and optimization of health resources.
“…13 In the present study, considering the median values of each cost item (hospitalization, intervention, procedures, and administrative cost), the largest contributors to a patient's total cost were the duration of the hospital stay and the length of the surgical intervention, equating to 47% and 32% of the total cost, respectively. The patient with the highest overall cost had a prolonged hospital stay (25 days) due to the presence of extra-hepatic cysts and the need for a longer observation period.…”
Abstract. Cystic echinococcosis (CE) is a globally distributed zoonosis caused by the Echinococcus granulosus sensu lato species complex. Four approaches are available for treatment of abdominal CE: surgery, percutaneous aspiration, chemotherapy with albendazole, and watch-and-wait. Allocation of patients to these different treatment options mainly depends on the stage of the cystic lesion. However, as available guidelines are not widely followed, surgery is often applied even without the correct indication outside referral centers. This is not only a disadvantage for the patient, but also a waste of money. In this study, we evaluated the cost of the surgical approach for abdominal CE by analyzing hospitalization costs for 14 patients admitted to the General Surgery Ward at the "San Matteo" Hospital Foundation in Pavia, Italy, from 2008 through 2014. We found that the total cost of a single hospitalization, including hospital stay, surgical intervention, personnel, drugs, and administrative costs ranged from 5,874 to 23,077 (median 11,033) per patient. Our findings confirm that surgery can be an expensive option. Therefore, surgical intervention should be limited to cyst types that do not benefit from nonsurgical therapies and appropriate case management can best be accomplished by using a cyst stage-specific approach.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.